PhenomeX optofluidic and proteomic technology to be featured
in several poster and podium presentations
EMERYVILLE, Calif., May 11, 2023
/PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell
biology company, today announced that it will participate in the
19th annual Protein Engineering & Cell Therapy
Summit (PEGS) Conference and Expo being held from May 15-19 at the Hynes Convention Center in
Boston, Mass.
At the conference, the Company will feature its optofluidic and
proteomic technologies in booth #517 and attendees can explore
demonstrations and learn more about how PhenomeX's products can
advance and accelerate our understanding of cellular function along
the continuum of scientific discovery, bioprocessing, clinical
research, and immunotherapy development.
At PEGS, PhenomeX technology is highlighted in two poster
presentations entitled:
- High-Throughput Cell-Free In Vitro Protein Expression,
Purification, and Functional Evaluation on Beacon Optofluidic
System
- Multi-omic Analysis for Directly Linking T Cell Phenotype to
Gene Expression
In addition, PhenomeX will lead two podium presentations
highlighting optofluidic applications with T cell immune-oncology
and bispecific cell line development:
- Troy Lionberger, Ph.D., Senior
Vice President, Business Development, PhenomeX
Topic: Accelerating functional TCR discovery by
phenotyping thousands of live, single T cells in two
days
Date: May 16, 2023, at
9:30 a.m. EST
Abstract: This presentation will introduce a high-throughput
screening technology platform capable of observing single T cells
in co-culture with antigen-presenting cells (APCs). During the
time-course observation, >1,000 single T cells are monitored for
their ability to kill APCs in co-culture, surface marker
expression, and cytokine secretion. Recovering functional T cells
from patient samples using this two-day workflow can accelerate
therapeutic TCR discovery, T cell vaccine development, and patient
immune monitoring.
- Alison Glaser, Applications
Scientist, PhenomeX
Topic: Miniaturized quality assays to accelerate
selection of clones producing a high percentage of bispecifics
heterodimer
Date: May 16,
2023, at 3:20 p.m. EST
Abstract: Microfluidic chips can be used to sort and clone
CHO cells, perform miniaturized assays, and recover top performers.
This automated process reduces the number of clones that must be
expanded and characterized, while simultaneously increasing the
likelihood of finding a cell line producing a high percentage of
bispecific heterodimer. In this presentation, data will be shared
demonstrating how miniaturized quality assays enable selection of
top performing clones within five days of cloning.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding PhenomeX or its products, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. PhenomeX undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties relating to the
Company's growth and continual evolution see the statements in the
"Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-to-participate-in-19th-annual-pegs-boston-conference--expo-301822270.html
SOURCE PhenomeX